Investment Rating - The report maintains a "Buy" rating for the company with a target price of 110.24 CNY, based on an expected transition from loss to profit by 2025 [2][5]. Core Insights - The company is expected to achieve a significant reduction in quarterly losses, with a focus on expanding its smart driving business and acquiring new customers and products [1][9]. - Revenue and profit forecasts have been adjusted, with projected EPS for 2025-2027 at 0.21, 2.08, and 3.16 CNY respectively, indicating a positive growth trajectory [2][4]. Financial Performance Summary - **Revenue**: The company is projected to generate revenues of 4,678 million CNY in 2023, increasing to 10,206 million CNY by 2027, reflecting a compound annual growth rate (CAGR) of approximately 19.5% [4][12]. - **Net Profit**: The company is expected to transition from a net loss of 217 million CNY in 2023 to a net profit of 379 million CNY by 2027, with significant year-on-year growth rates [4][12]. - **Gross Margin**: The gross margin is expected to stabilize around 24.1% by 2027, after a slight decline in the earlier years due to market competition [4][9]. - **Earnings Per Share (EPS)**: EPS is projected to improve from -1.81 CNY in 2023 to 3.16 CNY in 2027, indicating a strong recovery [4][12]. Business Segment Insights - **Automotive Electronics**: The automotive electronics segment is anticipated to grow significantly, with revenues expected to reach 44.06 billion CNY in 2024, driven by new product launches and customer acquisitions [9]. - **R&D Services**: The R&D services and solutions segment is projected to see a decline in revenue in 2024 but is expected to recover as the company engages with overseas clients [9][12]. Valuation Comparison - The report compares the company's valuation with peers, indicating an average PE ratio of 53 times for comparable companies in 2026, suggesting a premium valuation for the company [2][10].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 110.24 CNY, based on an expected transition from loss to profit by 2025 [2][5]. Core Insights - The company is expected to achieve a significant reduction in quarterly losses, with a focus on expanding its smart driving business and acquiring new customers and products [1][9]. - Revenue and profit forecasts have been adjusted, with projected EPS for 2025-2027 at 0.21, 2.08, and 3.16 CNY respectively, indicating a positive growth trajectory [2][4]. Financial Performance Summary - **Revenue**: Projected revenues are expected to grow from 4,678 million CNY in 2023 to 10,206 million CNY in 2027, reflecting a compound annual growth rate (CAGR) of approximately 19.5% [4][12]. - **Net Profit**: The company is forecasted to transition from a net loss of 217 million CNY in 2023 to a net profit of 379 million CNY by 2027, with significant year-on-year growth rates [4][12]. - **Gross Margin**: The gross margin is expected to stabilize around 24.1% by 2027, after a slight decline in the earlier years due to market competition [4][9]. - **Earnings Per Share (EPS)**: EPS is projected to improve from a loss of 1.81 CNY in 2023 to a profit of 3.16 CNY by 2027, indicating a strong recovery [4][12]. Business Segment Insights - **Automotive Electronics**: The automotive electronics segment is anticipated to grow significantly, with revenues expected to reach 44.06 billion CNY in 2024, driven by new product launches and customer acquisitions [9]. - **R&D Services**: The R&D services and solutions segment is projected to see a decline in revenue in 2024 but is expected to recover as overseas clients show increased interest in domestic supply chains [9][12].

造纸轻工行业 行业研究 | 行业周报 本周成品纸价格基本稳定 ——造纸产业链数据每周速递（2025/06/06） 核心观点 ⚫ 本周轻工制造行业指数上涨 2.18%，跑赢大盘 1.30pct；造纸子板块上涨 1.78%， 跑赢大盘 0.90pct。本周沪深 300 指数上涨 0.88%，轻工制造(申万)指数上涨 2.18%，跑赢大盘 1.30pct，在 28 个申万一级行业中位列第 8 位；二级行业中，造 纸子板块上涨 1.78%，跑赢大盘 0.90pct。本周轻工四大子板块按涨幅由大到小分别 为文娱用品、家具、造纸和包装印刷板块，分别上涨 5.51%、2.03%、1.78%、 1.21%。 产业链数据跟踪 投资建议与投资标的 ⚫ 文化纸步入行业淡季，浆纸价格下行，推荐林浆纸一体化行业龙头太阳纸业 (002078，买入)。同时建议关注特种纸领军企业仙鹤股份(603733，买入)，中高端 装饰原纸龙头华旺科技(605377，买入)以及食品包装纸细分龙头五洲特纸(605007， 增持)。废纸系纸种方面，展望 2025 年行业新增供给增速明显放缓，整体供需有望 逐步改善，推荐玖龙纸业(02689，买入)、山鹰国际( ...

金融工程 | 动态跟踪 ESG 基金规模突破 8200 亿，首只浮 动费率基金结募 风险提示 报告发布日期 2025 年 06 月 08 日 | | | 杨怡玲 | yangyiling@orientsec.com.cn | | --- | --- | --- | --- | | 研究结论 | | 1111111111 | 执业证书编号：S0860523040002 | | | | 陶文启 | taowenqi@orientsec.com.cn | | ⚫ | 基金市场热点跟踪：1. ESG 基金规模突破 8200 亿：随着全球绿色转型与可持续发 | | 执业证书编号：S0860524080003 | 多只信用债 ETF 纳入回购质押库申请获 批，多只北交所主题基金限购 2025-06-02 卡塔尔投资局受让华夏基金 10%股份，首 批新模式浮动管理费基金获批 2025-05-26 业内首只中证 A500 增强策略 ETF 成立， 近期货币基金密集限购 2025-05-18 有关分析师的申明，见本报告最后部分。其他重要信息披露见分析师申明之后部分，或请与您的投资代表联系。并请阅读本证券研究报告最后一页的免责申 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 32.47 CNY, based on a projected 2025 PE of 17 times [3][6]. Core Insights - The company's revenue and profit are expected to grow significantly, with projected net profits for 2025, 2026, and 2027 at 828 million, 1.096 billion, and 1.438 billion CNY respectively, reflecting a substantial increase from previous estimates [3][10]. - The company is experiencing strong demand from key customers, which is anticipated to drive continued performance improvements [10]. Financial Performance Summary - Revenue is projected to grow from 2.6 billion CNY in 2023 to 10.363 billion CNY in 2027, with year-on-year growth rates of 87.0%, 62.5%, 42.0%, 33.6%, and 29.2% respectively [5][10]. - The gross margin is expected to remain stable, with slight fluctuations, projected at 27.6% in 2024 and 26.5% in 2027 [5][10]. - The net profit margin is forecasted to improve from 11.9% in 2023 to 13.9% in 2027, indicating enhanced profitability [5][10]. - The company plans to distribute a cash dividend of 1.5 CNY per 10 shares to all shareholders in 2024 [10]. Customer Demand and Capacity Expansion - The company is closely tied to leading domestic brands and new energy vehicle manufacturers, which are expected to see significant sales growth, thereby benefiting the company's performance [10]. - The company is actively expanding its production capacity to meet increasing orders, with plans to establish new production bases in various locations [10].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 32.47 CNY, based on a projected PE of 17 times for 2025 [3][6]. Core Views - The company's revenue and profit are expected to grow rapidly, with projected net profits for 2025-2027 at 828 million, 1.096 billion, and 1.438 billion CNY respectively, reflecting significant growth compared to previous estimates [3][10]. - Strong demand from core customers is anticipated to drive continued performance improvement, with major clients such as Seres, Li Auto, Geely, and Xpeng showing robust sales growth [10]. - The company is actively expanding its production capacity to meet increasing orders, with plans to establish production bases in multiple locations [10]. Financial Summary - Revenue is projected to grow from 2.6 billion CNY in 2023 to 10.363 billion CNY in 2027, with year-on-year growth rates of 87.0%, 62.5%, 42.0%, 33.6%, and 29.2% respectively [5][10]. - The gross margin is expected to remain stable, with slight fluctuations, projected at 27.6% in 2024 and around 26.5% in 2027 [5][10]. - The net profit margin is forecasted to improve from 11.9% in 2023 to approximately 13.9% in 2027, indicating enhanced profitability [5][10]. - The company plans to distribute a cash dividend of 1.5 CNY per 10 shares to all shareholders in 2024 [10].

- The report discusses the impact of dividends on stock index futures, specifically for the contracts of the SSE 50, CSI 300, CSI 500, and CSI 1000 indices [1][2][3][4] - The latest dividend forecast model predicts the dividend points for the June contracts of the SSE 50, CSI 300, CSI 500, and CSI 1000 indices to be 12.10, 16.30, 18.75, and 17.78, respectively [8][11] - The annualized hedging costs (excluding dividends, calculated on a 365-day basis) for the June contracts of the SSE 50, CSI 300, CSI 500, and CSI 1000 indices are 3.05%, 1.54%, 8.11%, and 14.77%, respectively [8][11] - The report provides detailed data on the closing prices, dividend points, actual spreads, and dividend-inclusive spreads for the June, July, September, and December contracts of the SSE 50, CSI 300, CSI 500, and CSI 1000 indices [2][3][4] - The remaining impact of dividends on the June contracts of the SSE 50, CSI 300, CSI 500, and CSI 1000 indices is 0.45%, 0.42%, 0.33%, and 0.29%, respectively [12][13][14][15][16] - The report outlines the process for predicting dividends, which includes estimating the net profit of constituent stocks, calculating the total pre-tax dividends for each stock, and determining the impact of dividends on the index and each contract [9][21][24][25][26][27][28][29][30] - The theoretical pricing model for stock index futures is provided, including formulas for both discrete and continuous dividend distributions [32][33] Model and Factor Construction - **Model Name**: Dividend Impact Prediction Model - **Model Construction Idea**: The model aims to predict the impact of dividends on stock index futures contracts by estimating the dividends of constituent stocks and calculating their effect on the index and futures contracts [9][21] - **Model Construction Process**: 1. Estimate the net profit of constituent stocks using available information such as annual reports, quick reports, warnings, and analyst forecasts [23][24] 2. Calculate the total pre-tax dividends for each stock based on the estimated net profit and historical dividend rates [25][28] 3. Determine the impact of dividends on the index by calculating the dividend yield and the dividend points for each stock [26] 4. Estimate the ex-dividend dates and calculate the theoretical impact of dividends on each futures contract [27][29][30] 5. Use the theoretical pricing model for stock index futures to incorporate the impact of dividends into the futures prices [32][33] - **Model Evaluation**: The model provides a systematic approach to predict the impact of dividends on stock index futures, considering various factors such as net profit estimates, dividend rates, and ex-dividend dates [9][21][24] Model Backtesting Results - **SSE 50 Futures (June Contract)**: - Closing Price: 2673.60 - Dividend Points: 12.10 - Actual Spread: -15.25 - Dividend-Inclusive Spread: -3.15 - Remaining Impact: 0.45% - Annualized Hedging Cost (365 days): 3.05% - Annualized Hedging Cost (243 days): 2.84% [2][12] - **CSI 300 Futures (June Contract)**: - Closing Price: 3855.40 - Dividend Points: 16.30 - Actual Spread: -18.58 - Dividend-Inclusive Spread: -2.28 - Remaining Impact: 0.42% - Annualized Hedging Cost (365 days): 1.54% - Annualized Hedging Cost (243 days): 1.43% [2][13] - **CSI 500 Futures (June Contract)**: - Closing Price: 5725.40 - Dividend Points: 18.75 - Actual Spread: -36.68 - Dividend-Inclusive Spread: -17.93 - Remaining Impact: 0.33% - Annualized Hedging Cost (365 days): 8.11% - Annualized Hedging Cost (243 days): 7.56% [3][14] - **CSI 1000 Futures (June Contract)**: - Closing Price: 6100.20 - Dividend Points: 17.78 - Actual Spread: -52.64 - Dividend-Inclusive Spread: -34.87 - Remaining Impact: 0.29% - Annualized Hedging Cost (365 days): 14.77% - Annualized Hedging Cost (243 days): 13.77% [4][15]

Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical and biotechnology industry in China [6] Core Insights - The ASCO conference showcased significant breakthroughs in both foreign and domestic innovative drugs, highlighting the competitive strength of domestic companies [4][9] - A total of 73 research data entries from domestic companies were included in this year's ASCO, marking a historical high, with 32 being oral presentations and 11 classified as Late-Breaking Abstracts [9][13] - In the NSCLC (non-small cell lung cancer) sector, domestic research is leading globally, with promising data from dual antibodies and ADC (antibody-drug conjugates) [9][10] Summary by Sections Dual Antibodies - PD-1/VEGF dual antibodies are gaining attention, with significant transactions occurring in the market, indicating a heated competition [10][14] - SSGJ-707 from Sanofi has shown impressive efficacy in treating PD-L1 positive advanced NSCLC, with a clinical data showing a cORR of 64.7% and DCR of 97.1% in a specific dosage group [15][16] - PD-1/IL-2, a globally first dual-specific antibody, has demonstrated remarkable efficacy in late-stage NSCLC patients, with a 12-month OS rate of 71.6% [18][19] ADC (Antibody-Drug Conjugates) - ADC combined with immune checkpoint inhibitors is set to replace traditional chemotherapy, with domestic products expected to play a significant role [10][27] - The TROP2 ADC combined with PD-(L)1 has shown promising results in first-line treatment for advanced NSCLC, with an ORR of 55% [27][28] - Sac-TMT from Kelun Biotech has also shown superior efficacy in advanced NSCLC patients, particularly in those with high PD-L1 expression [30][31] Small Cell Lung Cancer (SCLC) - DLL3-targeted therapies have made significant progress, with domestic products demonstrating international competitiveness [10][39] - Tarlatamab has achieved breakthroughs in both second-line and first-line maintenance treatment for SCLC, expanding its indication [10][39] - Domestic DLL3 products have shown promising clinical data, indicating a strong potential for future development [10][39]

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Views - The company's EAST large scientific device has achieved a key technology breakthrough in steady-state high-parameter plasma, winning the Anhui Provincial Science and Technology Progress Award [1] - The recovery in downstream demand and the advancement of nuclear fusion projects are expected to drive growth across various business segments [1] Financial Forecast and Investment Recommendations - Revenue and gross margin have been adjusted downward based on industry demand, with EPS for 2025 and 2026 revised to 1.60 and 1.97 yuan respectively, and a new EPS for 2027 set at 2.41 yuan [2] - The target price is set at 67.20 yuan, corresponding to a 42x PE for 2025, maintaining the "Buy" rating [2] Key Financial Information - Projected revenue (in million yuan) for 2023A to 2027E: 4,159, 4,612, 6,028, 7,337, 8,839, with growth rates of -1.6%, 10.9%, 30.7%, 21.7%, and 20.5% respectively [3] - Projected net profit attributable to the parent company (in million yuan) for 2023A to 2027E: 752, 801, 1,042, 1,282, 1,567, with growth rates of -30.3%, 6.4%, 30.1%, 23.0%, and 22.3% respectively [3] - Projected EPS for 2023A to 2027E: 1.16, 1.23, 1.60, 1.97, 2.41 [3] - Projected gross margin for 2023A to 2027E: 31.9%, 33.6%, 33.9%, 34.7%, 35.4% [3] Business Developments - The company has achieved significant breakthroughs in superconducting materials, with multiple projects achieving mass supply, including superconducting wire for the EAST device and the domestic nuclear fusion CRAFT project [9] - The high-performance high-temperature alloy technology has seen key innovations, enhancing the company's competitive edge in the industry [9] - The high-end titanium alloy market is expanding, with successful development of new specifications and production technologies [9]

Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical and biotechnology industry in China [6] Core Insights - The ASCO conference showcased significant breakthroughs in both foreign and domestic innovative drugs, highlighting the competitive strength of domestic companies [4][9] - A total of 73 research data entries from domestic companies were included in this year's ASCO, marking a historical high [9][13] - The report emphasizes the potential of dual antibodies and antibody-drug conjugates (ADCs) in the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) [9][39] Summary by Sections Dual Antibodies - Domestic research is leading globally in dual antibodies, with products like PD-1/VEGF and PD-1/IL-2 showing promise as major drugs in the post-PD-1 era [9][10] - SSGJ-707 from Sanofi has shown impressive efficacy in treating advanced NSCLC, with a clinical data showing a cORR of 64.7% and DCR of 97.1% in specific patient groups [15][16] - IBI363, a first-in-class PD-1/IL-2 dual-specific antibody, has demonstrated significant efficacy in advanced NSCLC, with a median PFS of 9.3 months in squamous cell carcinoma patients [18][19] Antibody-Drug Conjugates (ADCs) - ADCs are expected to gradually replace existing standard of care (SOC) treatments, with domestic products poised to take a significant market share [10][39] - The TROP2 ADC combined with PD-(L)1 therapy has shown promising results in first-line treatment of advanced NSCLC, with an ORR of 55% and mPFS of 11.2 months [27][28] - Sac-TMT from Kelun Biotech has demonstrated superior efficacy compared to Dato-DXd, particularly in patients with high PD-L1 expression [30][31] Small Cell Lung Cancer (SCLC) - DLL3-targeted therapies have made significant progress, with domestic products showing international competitiveness [9][39] - Tarlatamab has achieved breakthroughs in both second-line and first-line maintenance treatment for SCLC, with promising clinical data [9][39] - The report highlights the potential of DLL3-targeted therapies to evolve from dual antibodies to ADCs, enhancing treatment options for SCLC patients [9][39]